Comparison of the Effects of Oral Sirolimus and Oral Cyclosporine on the Thrombocytopenic Chronic Purpura

Comparison the efficacy and safety of Oral Sirolimus and oral cyclosporine in the chronic thrombocytopenic purpura immune in children

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180501039499N1

Enrollment

Registered

2018-08-12

Start date

2018-10-17

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic thrombocytopenic purpura. Immune thrombocytopenic purpura

Interventions

Intervention 1: Control group: Patients in this group will receive oral cyclosporine 5 mg / kg / day twice a day for 6 months. Intervention 2: Intervention group: Receiving oral Sirolimus in this grou

Eligibility

Sex/Gender

All

Age

5 Years to 15 Years

Inclusion criteria

Inclusion criteria: Children aged 5 to 15 years with chronic idiopathic thrombocytopenic purpura Not having any other blood diseases Parental informed consent

Exclusion criteria

Exclusion criteria: Increase BUN / CR or decrease GFR by less than 50 ml / day. Seizure Allergic reaction Oral drug intolerance No response to drug treatment after 3 months.

Design outcomes

Primary

Measure	Time frame
Idiopathic thrombocytopenic purpura. Timepoint: Platelet measurement at the beginning of the study, months 1 to 6 after treatment. Method of measurement: The number of platelets is measured by using the Cell counter sysmax device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMorteza MousaviHasanzadeh

Arak University of Medical Sciences

Morteza.mousavi1993@gmail.com+98 86 3322 0099

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 26, 2026